Tag: opioid induced constipation treatment market demand

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Opioid-Induced Constipation Treatment Market Forecast: What Market Value Is Expected By 2030?

The market catering to treatments for opioid-induced constipation has experienced robust expansion recently. Projections indicate a rise from $1.9 billion in 2025 to $2.02 billion in 2026, reflecting a compound annual growth rate of 6.7%. This past expansion was fueled by several key factors: the extensive prescription of opioids for managing persistent pain, the insufficient efficacy of conventional laxative treatments, an increasing incidence of pain associated with cancer, a deficiency in therapies specifically designed for opioid-induced constipation early on, and a greater number of hospital admissions arising from adverse opioid reactions.

The market for treatments addressing opioid-induced constipation is projected for significant expansion over the forthcoming years, anticipating a valuation of $2.54 billion by 2030, fueled by a compound annual growth rate of 5.9%. This projected expansion stems from several key drivers: escalating demand for therapies centered on PAMORA, a consistent increase in long-term opioid prescriptions, particularly within an aging demographic, a heightened clinical emphasis on pain management approaches that prioritize the patient’s experience, enhanced accessibility through both online and traditional retail pharmacies, and augmented investments in the development of drugs for gastrointestinal conditions. Significant trends expected to shape this market during the forecast period involve a greater uptake of peripherally acting µ-opioid receptor antagonists, a growing inclination towards OIC therapies that specifically target the condition without compromising pain relief, an increased integration of both medicinal and non-medicinal treatment strategies, a stronger emphasis on enhancing the quality of life for individuals managing chronic pain, and a rising level of awareness alongside improved diagnosis rates for opioid-induced constipation.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Opioid-Induced Constipation Treatment Market Demand Drivers: What Is Fueling Industry Growth?

The increasing utilization of opioids for managing both cancer-related and non-cancer pain is anticipated to be a significant driver for the opioid-induced constipation treatment market’s expansion. Cancer pain stems from the disease itself or its therapeutic interventions, whereas non-cancer pain originates from conditions independent of malignancy. The prescription of opioids for these pain conditions is predominantly motivated by the necessity for effective management of moderate to severe pain, taking into account pain severity, duration, individual patient responses to alternative therapies, and the overarching therapeutic objective of enhancing life quality while diligently mitigating addiction risks and adverse effects. Treatments designed for opioid-induced constipation (OIC) offer relief to patients experiencing discomfort from opioid use, regardless of whether their pain is cancer-related or not. By alleviating this specific side effect, OIC treatments contribute to greater patient comfort, improved compliance with prescribed pain management plans, and an overall better quality of life without sacrificing the efficacy of pain relief. Illustrating this trend, the Centers for Disease Control and Prevention, a prominent US health authority, reported in November 2024 that in 2023, approximately 37.5 opioid prescriptions were dispensed for every 100 individuals. High dispensing rates were observed in states such as Arkansas with 71.5, Alabama with 71.4, Mississippi with 63.1, and Louisiana with 62.7 prescriptions per 100 individuals in 2023. Consequently, the elevated use of opioids for managing cancer and non-cancer pain directly fuels the growth trajectory of the market dedicated to treating opioid-induced constipation.

Opioid-Induced Constipation Treatment Market Categorization By Product Type And Application

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

Opioid-Induced Constipation Treatment Market Innovation Trends: Which Developments Are Transforming The Industry?

Within the market for treatments targeting opioid-induced constipation, prominent pharmaceutical entities are actively engaged in pioneering novel therapeutic approaches. Their efforts are particularly concentrated on the development of innovations like peripherally acting µ-opioid receptor antagonists (PAMORAs). These agents are designed for precise modulation of receptors within the gastrointestinal tract, aiming to elevate treatment effectiveness, foster greater patient adherence, and mitigate undesirable systemic reactions that can occur during opioid-based pain management. A key characteristic of PAMORAs is their ability to selectively impede µ-opioid receptors exclusively in the digestive system, without permeating the blood-brain barrier. This targeted action facilitates the restoration of normal bowel movements while preserving the pain-relieving effects provided by central pain management strategies, distinguishing them from conventional laxatives which fail to address the root cause of constipation stemming from receptor activity. Illustrating this advancement, in May 2025, Luye Pharma, a pharmaceutical firm headquartered in China, introduced Mimeixin, a formulation combining oral oxycodone and naloxone in a sustained-release tablet format, specifically engineered for OIC management. This once-daily treatment not only provides pain relief but also counteracts opioid activity in the gut, offering enhanced bowel regularity and a reduction in gastrointestinal adverse effects when contrasted with earlier treatment options. Consequently, Mimeixin presents a convenient solution for patients, integrating pain alleviation and constipation control into a single, easy-to-take medication.

Opioid-Induced Constipation Treatment Market Company Landscape And Strategic Competition

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Access The Complete Opioid-Induced Constipation Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Opioid-Induced Constipation Treatment Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Forecasted Market Size Figures For The Opioid-Induced Constipation Treatment Market In 2026 And 2030?

The opioid-induced constipation treatment market has demonstrated robust growth in recent years. It is forecast to increase from $1.9 billion in 2025 to $2.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. This historical expansion can be attributed to factors such as the extensive use of opioids for chronic pain management, the limited efficacy of traditional laxatives, the rising prevalence of cancer-related pain, a scarcity of early OIC-specific therapies, and a surge in hospitalizations due to opioid side effects.

The opioid-induced constipation treatment market size is anticipated to expand significantly in the coming years. By 2030, it is projected to reach $2.54 billion, exhibiting a compound annual growth rate (CAGR) of 5.9%. This expansion during the forecast period can be ascribed to several factors, including the escalating demand for PAMORA-based treatments, a rise in long-term opioid prescriptions among older demographics, a heightened clinical emphasis on patient-centric pain management, the broader availability of online and retail pharmacies, and increased investment in the development of gastrointestinal disorder drugs. Prominent developments expected in this period encompass a greater embrace of peripherally acting μ-opioid receptor antagonists, a growing inclination towards specific OIC treatments that do not compromise pain relief, an uptick in the application of combined pharmacological and non-pharmacological interventions, an amplified effort to enhance the quality of life for individuals with chronic pain, and an improved understanding and detection of opioid-induced constipation.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

What Are The Main Drivers Accelerating The Growth Of The Opioid-Induced Constipation Treatment Market?

The increasing use of opioids for managing both cancer-related and non-cancer pain is anticipated to fuel the expansion of the opioid-induced constipation treatment market in the coming years. Cancer pain describes discomfort linked to cancer and its therapies, whereas non-cancer pain denotes discomfort arising from conditions not related to cancer. The prescription of opioids for both types of pain is motivated by the necessity for effective management of moderate to severe pain, taking into account elements like pain intensity and duration, a patient’s reaction to alternative treatments, and the broader objective of enhancing life quality while mitigating potential risks of dependency and adverse reactions. Opioid-induced constipation (OIC) treatment assists individuals experiencing cancer and non-cancer pain by alleviating constipation resulting from opioid consumption, consequently boosting general comfort, compliance with pain management plans, and quality of life without diminishing pain relief. As an illustration, data released in November 2024 by the Centers for Disease Control and Prevention, a US-based public health agency, indicated that in 2023, there was a rate of 37.5 opioid prescriptions dispensed per 100 persons. Additionally, states recording the highest opioid dispensing rates per 100 persons in 2023 comprised Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the increased use of opioids for both cancer and non-cancer pain is stimulating the expansion of the opioid-induced constipation treatment market.

How Is The Opioid-Induced Constipation Treatment Market Structured Across Different Market Segments?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting μ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

What Trends Are Shaping The Opioid-Induced Constipation Treatment Market Structure?

Major companies within the opioid use disorder (OUD) market are concentrating on developing innovative solutions, such as next-generation extended-release buprenorphine formulations. This effort aims to meet the escalating demand for long-acting, adherence-supportive treatment options that mitigate withdrawal symptoms and improve recovery outcomes. Extended-release buprenorphine formulations provide sustained medication delivery over weekly or monthly periods, offering greater convenience and stability when compared with daily oral or sublingual therapies, which might increase the risk of relapse. For instance, in May 2023, the U.S. Food and Drug Administration, a US-based federal agency, approved Brixadi (buprenorphine) extended-release injection for treating moderate to severe opioid use disorder (OUD). Brixadi is available in two dosage forms: a weekly injection for patients who commenced treatment with a single dose of a transmucosal buprenorphine product or who are presently taking the medication, and a monthly version for those already receiving the medication.

Which Industry Players Are Present In The Opioid-Induced Constipation Treatment Market?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol‑Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann‑La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Access The Complete Opioid-Induced Constipation Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Which Area Represents The Largest Portion Of The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Opioid-Induced Constipation Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Opioids Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/opioids-global-market-report

Opioid Induced Constipation Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Migraine Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Opioid-Induced Constipation Treatment Market Between 2026 And 2030?

The opioid-induced constipation treatment market size has experienced robust expansion in recent years. This market is projected to expand from $1.9 billion in 2025 to $2.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. Historically, this market’s growth has been fueled by several factors, including the extensive use of opioids for managing chronic pain, the inadequate efficacy of conventional laxatives, the rising incidence of cancer-related pain, the absence of early OIC-specific treatments, and an increase in hospital admissions resulting from opioid side effects.

The market size for opioid-induced constipation treatment is anticipated to experience substantial expansion in the coming years. It is forecast to achieve $2.54 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.9%. This projected growth can be attributed to several factors, including an increasing demand for PAMORA-based therapies, a rise in long-term opioid prescriptions among aging populations, an amplified clinical focus on patient-centric pain management, the expansion of online and retail pharmacy access, and increased investment in drug development for gastrointestinal disorders. Significant trends for the forecast period involve the rising adoption of peripherally acting µ-opioid receptor antagonists, a growing preference for targeted OIC therapies that preserve analgesia, an expanding utilization of combined pharmacological and non-pharmacological treatments, an increasing emphasis on improving the quality of life for chronic pain patients, and enhanced awareness and diagnosis of opioid-induced constipation.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Which Major Drivers Are Influencing The Expansion Of The Opioid-Induced Constipation Treatment Market?

The increasing use of opioids for both cancer-related and non-cancer-related pain is anticipated to drive the expansion of the opioid-induced constipation treatment market in the future. Cancer pain is defined as discomfort stemming from cancer or its therapies, whereas non-cancer pain involves discomfort from conditions not linked to cancer. Opioids are prescribed for cancer and non-cancer pain primarily to manage moderate to severe discomfort efficiently. This decision takes into account the pain’s intensity and duration, the patient’s reaction to alternative treatments, and the broader objective of enhancing quality of life, all while reducing the potential for addiction and adverse effects. Treatment for opioid-induced constipation (OIC) assists individuals suffering from cancer and non-cancer pain by alleviating constipation induced by opioid use. This, in turn, boosts overall comfort, improves compliance with pain management plans, and enhances quality of life, without diminishing the effectiveness of pain relief. For example, data from November 2024, released by the US-based public health agency, the Centers for Disease Control and Prevention, indicated that in 2023, the opioid prescription dispensing rate was 37.5 per 100 persons. Additionally, in 2023, the states exhibiting the highest opioid dispensing rates per 100 individuals were Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the increased use of opioids for both cancer and non-cancer pain is stimulating the expansion of the opioid-induced constipation treatment market.

What Segment Categories Shape The Opioid-Induced Constipation Treatment Market Segment Landscape?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

Which Trends Are Shaping The Opioid-Induced Constipation Treatment Market?

Major companies in the opioid-induced constipation treatment market are prioritizing innovation, such as the development of peripherally acting µ-opioid receptor antagonists (PAMORAs). These compounds focus on targeted gut receptor modulation to improve efficacy, enhance patient compliance, and reduce systemic side effects during opioid therapy. A PAMORA operates by selectively blocking µ-opioid receptors within the gastrointestinal tract without crossing the blood–brain barrier, thereby restoring bowel function while maintaining central analgesia, a distinction from traditional laxatives which do not address the underlying receptor-mediated cause of constipation. For instance, in May 2025, Luye Pharma, a China-based pharmaceutical company, launched Mimeixin, an oral oxycodone/naloxone sustained-release tablet designed for OIC. This product provides once-daily pain relief while antagonizing gut opioid receptors, leading to improved bowel regularity and reduced gastrointestinal side effects compared to older therapies, offering a patient-friendly alternative that combines pain control and constipation management in a single tablet.

Who Are The Companies Operating Across The Opioid-Induced Constipation Treatment Market Value Chain?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Get The Full Opioid-Induced Constipation Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Which Region Is The Leading Market For The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Opioid-Induced Constipation Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Opioids Market Report 2026

https://www.thebusinessresearchcompany.com/report/opioids-global-market-report

Opioid Induced Constipation Treatment Market Report

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Migraine Treatment Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Opioid-Induced Constipation Treatment Market Evolve From 2026 To 2030?

The opioid-induced constipation treatment market has demonstrated substantial growth in recent years. It is anticipated to increase from $1.9 billion in 2025 to $2.02 billion in 2026, with a compound annual growth rate (CAGR) of 6.7%. The expansion observed historically can be attributed to several factors including the widespread administration of opioids for managing chronic pain, the limited effectiveness of traditional laxatives, the escalating prevalence of pain associated with cancer, the previous absence of early therapies specifically for OIC, and a rise in hospitalizations resulting from opioid-related adverse effects.

The opioid-induced constipation treatment market is anticipated to show significant expansion in the upcoming years. This market is projected to reach $2.54 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.9%. The anticipated expansion over the forecast period is primarily driven by the escalating demand for PAMORA-based therapies, the growing number of long-term opioid prescriptions for aging populations, an increasing clinical emphasis on patient-centered pain management, wider access through online and retail pharmacies, and greater investment in developing drugs for gastrointestinal disorders. Significant trends during this period are expected to involve the increasing uptake of peripherally acting µ-opioid receptor antagonists, a growing preference for targeted OIC treatments that do not compromise pain relief, an expanded application of combined pharmacological and non-pharmacological interventions, an elevated focus on enhancing the quality of life for chronic pain patients, and improved awareness and diagnosis of opioid-induced constipation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Opioid-Induced Constipation Treatment Market?

The projected growth of the opioid-induced constipation treatment market is linked to the increasing use of opioids for both cancer and non-cancer pain. Cancer pain refers to discomfort experienced due to cancer and its treatments, while non-cancer pain originates from conditions unrelated to cancer. Opioids are administered to effectively manage moderate to severe pain, considering aspects such as pain intensity and duration, patient response to other therapies, and the overarching goal of enhancing quality of life while minimizing potential addiction risks and side effects. Opioid-induced constipation (OIC) treatment offers relief to patients with cancer and non-cancer pain by alleviating constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, according to the Centers for Disease Control and Prevention, a US-based public health agency, in November 2024, the rate of opioid prescriptions dispensed in 2023 was 37.5 per 100 persons. Furthermore, states reporting the highest opioid dispensing rates per 100 persons in 2023 included Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the rising administration of opioids for cancer and non-cancer pain is driving the expansion of the opioid-induced constipation treatment market.

Which Segment Areas Are Covered In The Opioid-Induced Constipation Treatment Market Analysis?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

How Are Trends Shaping The Direction Of The Opioid-Induced Constipation Treatment Market?

Major companies in the opioid-induced constipation treatment market are focusing on developing innovative solutions, such as peripherally acting µ-opioid receptor antagonists (PAMORAs). These are designed for targeted modulation of gut receptors, aiming to increase efficacy, improve patient compliance, and reduce systemic side effects during opioid therapy. A PAMORA functions by selectively blocking µ-opioid receptors in the gastrointestinal tract without crossing the blood–brain barrier, thereby restoring bowel function while maintaining central analgesia. This mechanism differs from traditional laxatives, which do not address the fundamental receptor-mediated cause of constipation. For example, in May 2025, Luye Pharma, a China-based pharmaceutical company, launched Mimeixin, an oral oxycodone/naloxone sustained-release tablet specifically for OIC. This product provides once-daily analgesia while antagonizing gut opioid receptors, leading to improved bowel regularity and reduced gastrointestinal side effects compared to older therapies, offering patients a convenient alternative that combines pain control and constipation management in a single tablet.

Which Global Companies Are Actively Competing In The Opioid-Induced Constipation Treatment Market?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Read the full opioid-induced constipation treatment market report here:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

What Are The Leading Geographic Regions In The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Opioid-Induced Constipation Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Opioids Global Market Report

https://www.thebusinessresearchcompany.com/report/opioids-global-market-report

Opioid Induced Constipation Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Migraine Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Opioid-Induced Constipation Treatment Market Evolve From 2026 To 2030?

The opioid-induced constipation treatment market has demonstrated substantial growth in recent years. It is anticipated to increase from $1.9 billion in 2025 to $2.02 billion in 2026, with a compound annual growth rate (CAGR) of 6.7%. The expansion observed historically can be attributed to several factors including the widespread administration of opioids for managing chronic pain, the limited effectiveness of traditional laxatives, the escalating prevalence of pain associated with cancer, the previous absence of early therapies specifically for OIC, and a rise in hospitalizations resulting from opioid-related adverse effects.

The opioid-induced constipation treatment market is anticipated to show significant expansion in the upcoming years. This market is projected to reach $2.54 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.9%. The anticipated expansion over the forecast period is primarily driven by the escalating demand for PAMORA-based therapies, the growing number of long-term opioid prescriptions for aging populations, an increasing clinical emphasis on patient-centered pain management, wider access through online and retail pharmacies, and greater investment in developing drugs for gastrointestinal disorders. Significant trends during this period are expected to involve the increasing uptake of peripherally acting µ-opioid receptor antagonists, a growing preference for targeted OIC treatments that do not compromise pain relief, an expanded application of combined pharmacological and non-pharmacological interventions, an elevated focus on enhancing the quality of life for chronic pain patients, and improved awareness and diagnosis of opioid-induced constipation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Opioid-Induced Constipation Treatment Market?

The projected growth of the opioid-induced constipation treatment market is linked to the increasing use of opioids for both cancer and non-cancer pain. Cancer pain refers to discomfort experienced due to cancer and its treatments, while non-cancer pain originates from conditions unrelated to cancer. Opioids are administered to effectively manage moderate to severe pain, considering aspects such as pain intensity and duration, patient response to other therapies, and the overarching goal of enhancing quality of life while minimizing potential addiction risks and side effects. Opioid-induced constipation (OIC) treatment offers relief to patients with cancer and non-cancer pain by alleviating constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, according to the Centers for Disease Control and Prevention, a US-based public health agency, in November 2024, the rate of opioid prescriptions dispensed in 2023 was 37.5 per 100 persons. Furthermore, states reporting the highest opioid dispensing rates per 100 persons in 2023 included Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the rising administration of opioids for cancer and non-cancer pain is driving the expansion of the opioid-induced constipation treatment market.

Which Segment Areas Are Covered In The Opioid-Induced Constipation Treatment Market Analysis?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

How Are Trends Shaping The Direction Of The Opioid-Induced Constipation Treatment Market?

Major companies in the opioid-induced constipation treatment market are focusing on developing innovative solutions, such as peripherally acting µ-opioid receptor antagonists (PAMORAs). These are designed for targeted modulation of gut receptors, aiming to increase efficacy, improve patient compliance, and reduce systemic side effects during opioid therapy. A PAMORA functions by selectively blocking µ-opioid receptors in the gastrointestinal tract without crossing the blood–brain barrier, thereby restoring bowel function while maintaining central analgesia. This mechanism differs from traditional laxatives, which do not address the fundamental receptor-mediated cause of constipation. For example, in May 2025, Luye Pharma, a China-based pharmaceutical company, launched Mimeixin, an oral oxycodone/naloxone sustained-release tablet specifically for OIC. This product provides once-daily analgesia while antagonizing gut opioid receptors, leading to improved bowel regularity and reduced gastrointestinal side effects compared to older therapies, offering patients a convenient alternative that combines pain control and constipation management in a single tablet.

Which Global Companies Are Actively Competing In The Opioid-Induced Constipation Treatment Market?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Read the full opioid-induced constipation treatment market report here:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

What Are The Leading Geographic Regions In The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Opioid-Induced Constipation Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Opioids Global Market Report

https://www.thebusinessresearchcompany.com/report/opioids-global-market-report

Opioid Induced Constipation Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Migraine Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Opioid-Induced Constipation Treatment Market Evolve From 2026 To 2030?

The opioid-induced constipation treatment market has demonstrated substantial growth in recent years. It is anticipated to increase from $1.9 billion in 2025 to $2.02 billion in 2026, with a compound annual growth rate (CAGR) of 6.7%. The expansion observed historically can be attributed to several factors including the widespread administration of opioids for managing chronic pain, the limited effectiveness of traditional laxatives, the escalating prevalence of pain associated with cancer, the previous absence of early therapies specifically for OIC, and a rise in hospitalizations resulting from opioid-related adverse effects.

The opioid-induced constipation treatment market is anticipated to show significant expansion in the upcoming years. This market is projected to reach $2.54 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.9%. The anticipated expansion over the forecast period is primarily driven by the escalating demand for PAMORA-based therapies, the growing number of long-term opioid prescriptions for aging populations, an increasing clinical emphasis on patient-centered pain management, wider access through online and retail pharmacies, and greater investment in developing drugs for gastrointestinal disorders. Significant trends during this period are expected to involve the increasing uptake of peripherally acting µ-opioid receptor antagonists, a growing preference for targeted OIC treatments that do not compromise pain relief, an expanded application of combined pharmacological and non-pharmacological interventions, an elevated focus on enhancing the quality of life for chronic pain patients, and improved awareness and diagnosis of opioid-induced constipation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Opioid-Induced Constipation Treatment Market?

The projected growth of the opioid-induced constipation treatment market is linked to the increasing use of opioids for both cancer and non-cancer pain. Cancer pain refers to discomfort experienced due to cancer and its treatments, while non-cancer pain originates from conditions unrelated to cancer. Opioids are administered to effectively manage moderate to severe pain, considering aspects such as pain intensity and duration, patient response to other therapies, and the overarching goal of enhancing quality of life while minimizing potential addiction risks and side effects. Opioid-induced constipation (OIC) treatment offers relief to patients with cancer and non-cancer pain by alleviating constipation caused by opioid use, thereby improving overall comfort, adherence to pain management regimens, and quality of life without compromising pain relief. For instance, according to the Centers for Disease Control and Prevention, a US-based public health agency, in November 2024, the rate of opioid prescriptions dispensed in 2023 was 37.5 per 100 persons. Furthermore, states reporting the highest opioid dispensing rates per 100 persons in 2023 included Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Consequently, the rising administration of opioids for cancer and non-cancer pain is driving the expansion of the opioid-induced constipation treatment market.

Which Segment Areas Are Covered In The Opioid-Induced Constipation Treatment Market Analysis?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting µ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting µ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

How Are Trends Shaping The Direction Of The Opioid-Induced Constipation Treatment Market?

Major companies in the opioid-induced constipation treatment market are focusing on developing innovative solutions, such as peripherally acting µ-opioid receptor antagonists (PAMORAs). These are designed for targeted modulation of gut receptors, aiming to increase efficacy, improve patient compliance, and reduce systemic side effects during opioid therapy. A PAMORA functions by selectively blocking µ-opioid receptors in the gastrointestinal tract without crossing the blood–brain barrier, thereby restoring bowel function while maintaining central analgesia. This mechanism differs from traditional laxatives, which do not address the fundamental receptor-mediated cause of constipation. For example, in May 2025, Luye Pharma, a China-based pharmaceutical company, launched Mimeixin, an oral oxycodone/naloxone sustained-release tablet specifically for OIC. This product provides once-daily analgesia while antagonizing gut opioid receptors, leading to improved bowel regularity and reduced gastrointestinal side effects compared to older therapies, offering patients a convenient alternative that combines pain control and constipation management in a single tablet.

Which Global Companies Are Actively Competing In The Opioid-Induced Constipation Treatment Market?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol-Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann-La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Read the full opioid-induced constipation treatment market report here:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

What Are The Leading Geographic Regions In The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Opioid-Induced Constipation Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Opioids Global Market Report

https://www.thebusinessresearchcompany.com/report/opioids-global-market-report

Opioid Induced Constipation Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Migraine Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the opioid-induced constipation treatment market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Opioid-Induced Constipation Treatment Market be in 2030 compared with 2026?

The opioid-induced constipation treatment market size has seen strong expansion in recent years. It is forecast to increase from $1.9 billion in 2025 to $2.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. The market’s historical growth can be linked to factors such as the extensive use of opioids for managing chronic pain, the insufficient efficacy of conventional laxatives, the increasing prevalence of pain associated with cancer, the lack of early OIC-specific treatments, and a rise in hospitalizations stemming from opioid adverse effects.

The opioid-induced constipation treatment market size is anticipated to expand substantially in the coming years. It is projected to reach $2.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.9%. This expansion during the forecast period is fueled by several factors, including the increasing demand for PAMORA-based therapies, a rise in long-term opioid prescriptions among older demographics, a greater clinical emphasis on patient-centric pain management, the widening availability of online and retail pharmacies, and increased investment in the development of drugs for gastrointestinal disorders. Noteworthy trends for the forecast period encompass a greater adoption of peripherally acting μ-opioid receptor antagonists, a growing inclination towards targeted OIC therapies that do not compromise analgesia, an expanded application of combined pharmacological and non-pharmacological treatments, a heightened focus on enhancing the quality of life for individuals with chronic pain, and an improved awareness and diagnosis of opioid-induced constipation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

What Drivers Are Guiding Growth Patterns In The Opioid-Induced Constipation Treatment Market?

The increasing administration of opioids for both cancer and non-cancer pain is projected to advance the opioid-induced constipation treatment market. Cancer pain relates to discomfort associated with cancer and its remedies, while non-cancer pain originates from conditions unrelated to cancer. The use of opioids for cancer and non-cancer pain is essential for effectively managing moderate to severe pain, taking into account elements such as pain intensity and duration, patient response to alternative treatments, and the overarching aim of enhancing quality of life while minimizing potential addiction risks and adverse effects. Opioid-induced constipation (OIC) treatment aids patients suffering from cancer and non-cancer pain by alleviating constipation caused by opioid consumption, thereby improving overall comfort, adherence to pain management plans, and quality of life without compromising pain relief. For example, in November 2024, information from the Centers for Disease Control and Prevention, a US-based public health agency, indicated that in 2023, the rate was 37.5 opioid prescriptions dispensed per 100 persons. Additionally, states with the highest opioid dispensing rates per 100 persons in 2023 included Arkansas (71.5), Alabama (71.4), Mississippi (63.1), and Louisiana (62.7). Thus, the increased administration of opioids for cancer and non-cancer pain is stimulating the expansion of the opioid-induced constipation treatment market.

How Is The Opioid-Induced Constipation Treatment Market Divided Into Segments?

The opioid-induced constipation treatment market covered in this report is segmented –

1) By Drug Class: Laxatives, Peripherally Acting μ-opioid Receptor Antagonists, Serotonin Receptor Agonists

2) By Type: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives

2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan

3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod

What Industry Trends Are Transforming The Opioid-Induced Constipation Treatment Market?

Key companies operating in the opioid-induced constipation treatment market are prioritizing the development of innovations such as peripherally acting μ-opioid receptor antagonists (PAMORAs). These are engineered for targeted modulation of gut receptors, aiming to boost efficacy, improve patient adherence, and mitigate systemic adverse effects during opioid therapy. A PAMORA operates by selectively blocking μ-opioid receptors in the gastrointestinal tract without crossing the blood–brain barrier, thereby restoring bowel function while maintaining central analgesia, unlike traditional laxatives which do not address the underlying receptor-mediated cause of constipation. As an illustration, in May 2025, Luye Pharma, a China-based pharmaceutical company, introduced Mimeixin, an oral oxycodone/naloxone sustained-release tablet specifically formulated for OIC. This product delivers once-daily analgesia while simultaneously antagonizing gut opioid receptors, leading to improved bowel regularity and reduced gastrointestinal side effects compared to older therapies, thus providing a patient-friendly option that combines pain control and constipation management in a single tablet.

Which Key Players Are Driving Competition In The Opioid-Induced Constipation Treatment Market?

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol‑Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann‑La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, Daewoong Pharmaceutical Company

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Opioid-Induced Constipation Treatment Market?

North America was the largest region in the opioid-induced constipation treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Opioid-Induced Constipation Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

Browse Through More Reports Similar to the Global Opioid-Induced Constipation Treatment Market 2026, By The Business Research Company

Migraine Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Constipation Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/constipation-treatment-global-market-report

Constipation Laxative Market Report 2026

https://www.thebusinessresearchcompany.com/report/constipation-laxative-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model